Published in Medicine and Law Weekly, September 28th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at MedImmune, Inc.
Report 1: MedImmune, Inc. announced that it has begun dosing at-risk children six months to 24 months of age in a Phase 1 trial of a vaccine designed to help prevent respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV-3) infections, two of the most important causes of lower respiratory tract illness and hospitalization in infants and young children. A previously completed study in healthy adults and non-susceptible older children...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly